Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density?

Oncology Reports

Volumn 20, Issue 3, 2008, Pages 485-492

  Barresi, Valeria ^a,b   Alafaci, C ^a   Salpietro, F ^a   Tuccari, G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

CD105; Immunohistochemistry; Meningioma; Microvessel density; Somatostatin receptor 2A; Therapy

Indexed keywords

ENDOGLIN; KI 67 ANTIGEN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MALE; MENINGIOMA; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING; TUMOR VASCULARIZATION; CANCER STAGING; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 54549086670     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000032     Document Type: Article

References (40)

1. Epelbaum J, Dournaud P, Fodor M and Viollet C: The neurobiology of somatostatin. Crit Rev Neurobiol 8: 25-44, 1994.
2. Epelbaum J: Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 27: 63-100, 1986.
3. Reubi JC and Laissue JA: Multiple action of somatostatin in neoplastic disease. Trends Pharmacol Sci 16: 110-115, 1995.
4. Ribatti D, Conconi MT and Nussdorfer GG: Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 59: 185-205, 2007.
5. Florio T: Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 13: 822-840, 2008.
6. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198, 1999.
7. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H and Srikant CB: Multiple gene transcription of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 192: 288-294, 1993.
8. Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW and Schonbrunn A: Immunohistochemical detection of sst2A receptor in lymphatic, smooth muscular, and peripheral nervous system of human gastrointestinal tract: facts and artefacts. J Clin Endocrinol Metab 84: 2942-2950, 1999.
9. Breder CD, Yamada Y, Yasuda K, Seino S, Saper CB and Bell GI: Differential expression of somatostatin receptor subtypes in brain. J Neurosci 12: 3920-3934, 1992.
10. Goodyer CG, Grigorakis SI, Patel YC and Kumar U: Developmental changes in the expression of somatostatin receptors (1-5) in the brain, hypothalamus, pituitary and spinal cord of the human fetus. Neuroscience 125: 441-448, 2004.
11. Lamberts SW, Krenning EP and Reubi JC: The role of somatostatin and its analogous in the diagnosis and treatment of tumours. Endocr Rev 12: 450-482, 1991.
12. Reubi JC, Waser B, Schaer JC and Markwalder R: Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 80: 2806-2814, 1995.
13. Schaer JC, Waser B, Mengod G and Reubi JC: Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70: 530-537, 1997.
14. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R and Patel YC: Expression of somatostatin receptor subtypes in human brain tumours. Int J Cancer 76: 620-627, 1998.
15. Reubi JC, Waser B, Liu Q, Laissue JA and Schonbrunn A: Subcellular distribution of somatostatin sst2A receptors in human tumours of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 85: 3882-3890, 2000.
16. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW and Schonbrunn A: Immunohistochemical localization of somatostatin receptors sst2A in human tumours. Am J Pathol 153: 233-245, 1998.
17. Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R and Höllt V: Immunohistochemical determination of five somatostatin receptors in meningiomas reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6: 1865-1874, 2000.
18. Arena S, Barbieri F, Thellung S, et al: Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66: 155-166, 2004.
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon, 2007.
20. Kayaselçuk F, Zorludemir S, Bal N, Erdogan B, Erdogan S and Erman T: The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome. J Neurooncol 67: 209-214, 2004.
21. Pistolesi S, Boldrini L, Gisfredi S, et al: Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 30: 118-125, 2004.
22. Barresi V, Cerasoli S, Vitarelli E and Tuccari G: Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 114: 147-156, 2007.
23. Simpson D: The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20: 22-39, 1957.
24. Weir EE, Pretlow TG and Pitts A: A more sensitive and specific histochemical peroxidase stain for the localization of cellular antigen by the enzyme-antibody conjugated method. J Histochem Cytochem 22: 1135-1140, 1974.
25. Gougos A, St Jacques S, Greaves A, et al: Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4: 83-92, 1992.
26. Qiu CZ, Wang C, Huang ZX, Zhu SZ, Wu YY and Qiu JL: Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer. World J Gastroenterol 12: 2011-2015, 2006.
27. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
28. Perry A, Stafford SL, Scheithauer BW, Suman VJ and Lohse CM: The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82: 2262-2269, 1998.
29. Reubi JC, Maurer R, Klijn JG, et al: High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 63: 433-438, 1986.
30. Hildebrandt G, Scheidhauer K, Luyken C, Schicha H, Klug N, Dahms P and Krisch B: High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients. Acta Neurochir 126: 63-71, 1994.
31. Lawnicka H, Stepien H, Wyczólkowska J, Kolago B, Kunert-Radek J and Komorowski J: Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 268: 567-571, 2000.
32. Cheifetz S, Bellon T, Cales C, et al: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
33. Burrows FJ, Derbyshire EJ, Tazzari PL, et al: Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
34. Wang JM, Kumar S, Pye D, van Aghtoven AJ, Krupinski J and Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54: 363-370, 1993.
35. Fonsatti E, Altomonte M, Arslan P and Maio M: Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 3: 427-432, 2003.
36. Dallago CM, Oliveira MC, Barbosa-Coutinho LM and Ferreira NP: Angiogenesis in craniopharyngiomas: Microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin. Endocr Pathol 16: 355-362, 2005.
37. Yao Y, Kubota T, Takeuchi H and Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25: 201-206, 2005.
38. Christov C, Lechapt-Zalcman E, Adle-Biassette H, Nachev S and Gherardi RK: Vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) and its receptor flt-1 in microcystic meningiomas. Acta Neuropathol 98: 414-420, 1999.
39. Volante M, Brizzi MP, Faggiano A, et al: Somatostatin receptor type 2° immunohistochemistry in neuroendocrine tumours: a proposal of a scorino system correlated with somatostatin receptor scintigraphy. Modern Pathol 20: 1172-1182, 2007.
40. Chamberlain MC, Glantz MJ and Fadul CE: Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69: 969-973, 2007.